Hwa Jung Choi

Dr. Hwa Jung Choi


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2011 in Virology Journal
Verified
Journal Article
Open access
PDF file
JSJae-Hyoung Song
Jae-Hyoung Song
JSJae Kwon Shim
Jae Kwon Shim
HCHwa Jung Choi
Hwa Jung Choi
Background: On the base of our previous study we were observed relevant studies on the hypothesis that the antiviral activity of quercetin 7-rhamnoside (Q7R), a flavonoid, won't relate ability of its antioxidant. Methods: We were investigated the effects of Q7R on the cytopathic effects (CPE) by CPE reduction assay. Production of DNA fragment and reactive oxygen species (ROS) induced by PEDV infection were studied using DNA fragmentation assay and flow cytometry. Results: In the course of this study it was discovered that Q7R is an extremely potent compound against PEDV. The addition of Q7R to PEDV-infected Vero cells directly reduced the formation of a visible cytopathic effect (CPE). Also, Q7R did not induce DNA fragmentation. Furthermore, ROS increased the infection of PEDV, which was strongly decreased by N-acetyl-L-cysteins (NAC). However, the increased ROS was not decreased by Q7R. Antiviral activity of antioxidants such as NAC, pyrrolidine dithiocarbamate (PDTC), and the vitamin E derivative, trolox, were hardly noticed. Conclusions: We concluded that the inhibition of PEDV production by Q7R is not simply due to a general action as an antioxidants and is highly specific, as several other antioxidants (NAC, PDTC, trolox) are inactive against PEDV infection.

31 December 2017 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
PDF file
HCHwa Jung Choi
Hwa Jung Choi
Hwa-Jung Choi. Osong Public Health and Research Perspectives 2017;8:415-20. https://doi.org/10.24171/j.phrp.2017.8.6.09

Verified
Journal Article
Open access
PDF file
WKWoong-Hyun Kim
Woong-Hyun Kim
HSHyun-Ok Song
Hyun-Ok Song
HCHwa Jung Choi
Hwa Jung Choi
HBHo-Il Bang
Ho-Il Bang
DCDu-Young Choi
Du-Young Choi
HPHyun Park
Hyun Park
Many phytochemicals have been recognized to have potential therapeutic efficacy in cancer treatment. In this study, we investigated ethyl gallate (EG) for possible proapoptotic effects in the human promyelocytic leukemia cell line, HL-60. We examined cell viability, morphological changes, DNA content and fragmentation, and expression of apoptosis-related proteins for up to 48 h after EG treatment. The results showed that EG induced morphological changes and DNA fragmentation and reduced HL-60 cell viability in a dose-dependent and time-dependent manner. Western blotting analysis indicated that EG-mediated HL-60 apoptosis mainly occurred through the mitochondrial pathway, as shown by the release of cytochrome c, apoptosis-inducing factor (AIF), and endonuclease G (Endo G), as well as the upregulation of Bcl-2-associated X protein (Bax). EG also activated the death receptor-dependent pathway of apoptosis by enhancing the expression of caspases-8, -9, and -3 and the Bcl-2 interacting domain (Bid). Collectively, our results showed that EG induces apoptosis in HL-60 via mitochondrial-mediated pathways.

5 September 2018 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
DKDur‐Han Kwon
Dur‐Han Kwon
JJJeong‐Hun Ji
Jeong‐Hun Ji
SYSoon‐Ho Yim
Soon‐Ho Yim
BKByoung Soo Kim
Byoung Soo Kim
HCHwa Jung Choi
Hwa Jung Choi

1 December 2016 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
HCHwa Jung Choi
Hwa Jung Choi
Human rhinoviruses and enteroviruses (family Picornaviridae) infect millions of people worldwide each year, but little is known about effective therapeutical treatment for the infection caused by these viruses. We sought to determine whether or not Zanthoxylum (Rutaceae) species can exhibit antiviral activity against picornaviruses. The leaf parts of four Zanthoxylum species were extracted with methanol, and the extracts were investigated for their antiviral activity against picornaviruses using cytopathic effects by cytopathic effect reduction. Leaf extracts of Zanthoxylum piperitum among four Zanthoxylum species were found to possess only broad-spectrum antipicornavirus activity against human rhninovirus 2 with a 50% inhibitory concentration (IC50) value of 59.48 μg/mL, human rhinovirus 3 with an IC50 value of 39.94 μg/mL, coxsackie A16 virus with an IC50 value of 45.80 μg/mL, coxsackie B3 virus with an IC50 value of 68.53 μg/mL, coxsackie B4 virus with an IC50 value of 93.58 μg/mL, and enterovirus 71 virus with an IC50 value of 4.48 μg/mL. However, ribavirin did not possess antiviral activity against human rhinovirus 3 and four enteroviruses. Therefore, leaves of Z. piperitum showed broad-spectrum antipicornavirus activity, and may be useful as a candidate for studying picornavirus agents and development of pharmaceuticals.

10 October 2012 in Marine Drugs
Verified
Journal Article
Open access
PDF file
SPSoon-Hye Park
Soon-Hye Park
JSJae-Hyoung Song
Jae-Hyoung Song
TKTaejung Kim
Taejung Kim
WSWoon-Seob Shin
Woon-Seob Shin
GPGab Man Park
Gab Man Park
JHJungyeob Ham
Jungyeob Ham
An extract of the red alga, Neorhodomela aculeata, exhibited antiviral activity against human rhinoviruses. Bioassay-guided purification was performed to yield six compounds, which were subsequently identified as lanosol (1) and five polybromocatechols (2–6) by spectroscopic methods, including 1D and 2D NMR and mass spectrometric analyses. Structurally, all of these compounds, except compound 5, contain one or two 2,3-dibromo-4,5-dihydroxyphenyl moieties. In a biological activity assay, compound 1 was found to possess antiviral activity with a 50% inhibitory concentration (IC50) of 2.50 μg/mL against HRV2. Compound 3 showed anti-HRV2 activity, with an IC50 of 7.11 μg/mL, and anti-HRV3 activity, with an IC50 of 4.69 μg/mL, without demonstrable cytotoxicity at a concentration of 20 μg/mL. Collectively, the results suggest that compounds 1 and 3 are candidates for novel therapeutics against two different groups of human rhinovirus.